{"schema_version":"secwatch.filing_event.v1","accession":"0001607062-21-000355","form_type":"8-K","ticker":"RGBP","cik":"0001589150","company_name":"Regen BioPharma Inc","filed_at":"2021-09-27T23:59:59+00:00","discovered_at":"2026-05-14T18:04:18.703436+00:00","generated_at":"2026-06-29T01:17:20.816754+00:00","sec_items":["8.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Regen Biopharma receives USPTO Notice of Allowance for NR2F6 activity modulators patent","bullets":["Notice of Allowance issued Sept 23, 2021 for patent on small molecule agonists/antagonists of NR2F6.","Invention relates to compounds that alter NR2F6 activity, a nuclear receptor involved in immune regulation.","Allowed patent strengthens Regen's IP position for its small molecule immunomodulator program."],"urls":{"canonical":"https://secwatch.observer/filing/0001607062-21-000355","json":"https://secwatch.observer/filing/0001607062-21-000355.json","markdown":"https://secwatch.observer/filing/0001607062-21-000355.md","text":"https://secwatch.observer/filing/0001607062-21-000355.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1589150/000160706221000355/0001607062-21-000355-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1589150/000160706221000355/rgbp092721form8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-29T01:17:20.816754+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}